



World Anti-Doping Programme

# **THERAPEUTIC USE EXEMPTION GUIDELINES**

Version **56.0**

January 201~~1~~2

# TABLE OF CONTENTS

<b>Introduction and scope .....</b>	<b>95</b>
<b>Definitions .....</b>	<b>106</b>
<b>Terms defined in the Code .....</b>	<b>106</b>
<b>Terms defined in the International Standard for TUEs .....</b>	<b>1410</b>
<b>1. TUE procedure .....</b>	<b>1611</b>
<b>1.1. TUE procedure .....</b>	<b>1611</b>
1.1.1. General procedure for Prohibited Substances and Methods 1611	
1.1.2. Criteria for granting a TUE .....	1812
1.1.3. Retroactive TUEs .....	1913
<b>1.2. Documentation/information .....</b>	<b>2014</b>
1.2.1. What is sufficient? .....	2014
1.2.2. Who decides what is sufficient? .....	2115
1.2.3. Incomplete TUE applications .....	2116
1.2.4. TUE application forms .....	2216
1.2.5. TUE applications received via ADAMS .....	2216
1.2.6. Renewal of TUEs .....	2216
1.2.7. Duration of validity .....	2317
<b>1.3. Languages used .....</b>	<b>2317</b>
1.3.1. Application forms .....	2317
1.3.2. Medical information .....	2318
<b>1.4. Data protection .....</b>	<b>2418</b>
1.4.1. Athlete consent .....	2418

1.4.2. Confidentiality clause for people working with data.....	2418
1.4.3. For how long is this information stored?.....	2418
1.4.4. Modification of information .....	2418
<b>2. Role of ADOs.....</b>	<b>2519</b>
<b>2.1. ADO functions.....</b>	<b>2519</b>
2.1.1. Setting up a TUEC.....	2519
2.1.2. 30-day deadline .....	2620
2.1.3. Failure to comply with the International Standard for TUEs	2620
2.1.4. Registered testing pool .....	2620
<b>2.2. ADO jurisdiction: who grants TUEs? .....</b>	<b>2721</b>
2.2.1. International Federations (IF) for international-level <i>a</i> Athletes .....	2721
2.2.2. National Anti-Doping Organisations (NADOs) and National Federations (NFs) for national-level <i>a</i> Athletes .....	2822
2.2.3. What must a national-level do upon becoming an international-level ? .....	2822
<b>2.3. Mutual recognition: validity of TUEs among ADOs .....</b>	<b>2822</b>
2.3.1. Mutual recognition and the CODE.....	2822
2.3.2. TUEs granted by IFs compared to TUEs granted by NADOs and NFs.....	2923
2.3.3. IF recognition of TUEs granted by NADOs.....	3024
<b>2.4. Forwarding information.....</b>	<b>3124</b>
2.4.1. NADO responsibilities.....	3124
2.4.2. IF responsibilities .....	3125
<b>2.5. Results management.....</b>	<b>3125</b>
2.5.1. Results management for controls organised by an ADO.....	3125
2.5.2. Consultation among ADOs .....	3226

2.5.3. Existing TUEs and corresponding level of Prohibited Substance .....	3226
2.5.4. Existing TUEs whereby the level of the Prohibited Substance does not correspond to the TUE.....	3226
2.5.5. Absence of a TUE .....	3226
<b>3. Role of WADA .....</b>	<b>3428</b>
<b>3.1. Data management role: ADAMS.....</b>	<b>3428</b>
3.1.1. What is ADAMS? .....	3428
3.1.2. ADAMS and TUEs .....	3428
3.1.3. ADAMS and Athletes .....	3428
3.1.4. ADAMS and physicians.....	3529
3.1.5. ADAMS and ADOs .....	3529
<b>3.2. Role of monitoring and reviewing TUEs on its own initiative .....</b>	<b>3529</b>
<b>3.3. Role of reviewing TUEs at the request of an .....</b>	<b>3529</b>
3.3.1. TUE review procedure.....	3529
3.3.2. Appeal of decisions handed down by WADA .....	3731
<b>References .....</b>	<b>3933</b>
<b>Annex.....</b>	<b>4034</b>
<del>Introduction and scope .....</del>	<del>4</del>
<del>Definitions.....</del>	<del>5</del>
<del>Terms defined in the Code.....</del>	<del>5</del>
<del>Terms defined in the International Standard for TUEs.....</del>	<del>8</del>
<del>1. TUE procedure.....</del>	<del>9</del>
<del>1.1. TUE procedure.....</del>	<del>9</del>
<del>1.1.1. General procedure for prohibited substances and methods .....</del>	<del>9</del>
<del>1.1.2. Specific procedure for asthma treated with inhaled beta-2 agonists .....</del>	<del>10</del>

1.1.3. Criteria for granting a TUE.....	10
1.1.4. Retroactive TUEs.....	11
<b>1.2. Documentation/information.....</b>	<b>12</b>
1.2.1. What is sufficient?.....	12
1.2.2. Who decides what is sufficient?.....	13
1.2.3. Incomplete TUE applications.....	13
1.2.4. TUE application forms.....	13
1.2.5. TUE applications received via ADAMS.....	14
1.2.6. Renewal of TUEs.....	14
1.2.7. Duration of validity.....	14
<b>1.3. Languages used.....</b>	<b>15</b>
1.3.1. Application forms.....	15
1.3.2. Medical information.....	15
<b>1.4. Data protection.....</b>	<b>15</b>
1.4.1. Athlete consent.....	15
1.4.2. Confidentiality clause for people working with data.....	15
1.4.3. For how long is this information stored?.....	15
1.4.4. Modification of information.....	16
<b>2. Role of ADOs.....</b>	<b>16</b>
<b>2.1. ADO functions.....</b>	<b>16</b>
2.1.1. Setting up a TUEC.....	16
2.1.2. 30-day deadline.....	17
2.1.3. Failure to comply with the International Standard for TUEs....	17
2.1.4. Registered testing pool.....	17
<b>2.2. ADO jurisdiction: who grants TUEs?.....</b>	<b>18</b>
2.2.1. International Federations (IF) for international level athletes.	18

2.2.2. National Anti-Doping Organisations (NADOs) and National Federations (NFs) for national-level athletes .....	18
2.2.3. What must a national-level athlete do upon becoming an international-level athlete? .....	19
<b>2.3. Mutual recognition: validity of TUEs among ADOs .....</b>	<b>19</b>
2.3.1. Mutual recognition and the WADC .....	19
2.3.2. TUEs granted by IFs compared to TUEs granted by NADOs and NFs.....	20
2.3.3. IF recognition of TUEs granted by NADOs.....	20
<b>2.4. Forwarding information.....</b>	<b>21</b>
2.4.1. NADO responsibilities.....	21
2.4.2. IF responsibilities .....	21
<b>2.5. Results management.....</b>	<b>21</b>
2.5.1. Results management for controls organised by an ADO.....	21
2.5.2. Consultation among ADOs.....	22
2.5.3. Existing TUEs and corresponding level of prohibited substance .....	22
2.5.4. Existing TUEs whereby the level of the prohibited substance does not correspond to the TUE.....	22
2.5.5. Absence of a TUE .....	22
<b>3. Role of WADA .....</b>	<b>23</b>
<b>3.1. Data management role: ADAMS.....</b>	<b>23</b>
3.1.1. What is ADAMS? .....	23
3.1.2. ADAMS and TUEs .....	23
3.1.3. ADAMS and athletes .....	24
3.1.4. ADAMS and physicians.....	24
3.1.5. ADAMS and ADOs .....	24
<b>3.2. Role of monitoring and reviewing TUEs on its own initiative .....</b>	<b>24</b>

<b>3.3. Role of reviewing TUEs at the request of an athlete .....</b>	<b>24</b>
3.3.1. TUE review procedure.....	24
3.3.2. Appeal of decisions handed down by WADA .....	25
<b>References .....</b>	<b>27</b>
<b>Annex.....</b>	<b>28</b>

**±**



## Introduction and scope

These Therapeutic Use Exemption (TUE) Guidelines are a model for best practice developed as part of the World Anti-Doping Programme. They are based on the World Anti-Doping Code (*Code* or ~~WADCCODE~~) and the International Standard for TUEs established through the *Code*. These guidelines should, in particular, be read in conjunction with the principles set out in Article 4.4 of the ~~WADCCode~~. They have been developed in order to guide and assist competent *Anti-Doping Organisations (ADOs)* throughout the entire TUE procedure.

As a model for best practice, these guidelines are not mandatory and have no legal status. Only the International Standard for TUEs is mandatory and, in the *event* of any differences or ambiguities between the present guidelines and the International Standard for TUEs, the latter shall prevail.

*ADOs* are free to decide how to incorporate these guidelines into their own rules and procedures. They may be incorporated in full or in part, and may be amended or reworded to best fit the requirements of the *ADO*.

## 2 Definitions

### 2.1 Terms defined in the Code

**Adverse Analytical Finding:** A report from a laboratory or other WADA-approved entity that, consistent with the *International Standard* for Laboratories and related Technical Documents, identifies in a *Sample* the presence of a *Prohibited Substance* or its *Metabolites* or *Markers* (including elevated quantities of endogenous ~~substance~~Substances) or evidence of the *Use of a Prohibited Method*.

**Anti-Doping Organisation (ADO):** A *Signatory* that is responsible for adopting rules for initiating, implementing or enforcing any part of the *Doping Control* process. This includes, for example, the *International Olympic Committee*, the *International Paralympic Committee*, other *Major Event Organisations* that conduct *Testing* at their *Events*, WADA, *International Federations* and *National Anti-Doping Organisations*.

**Athlete:** Any *Person* who participates in sport at the international-level (as defined by each *International Federation*), the national-level (as defined by each *National Anti-Doping Organisation*, including but not limited to those *Persons* in its *Registered Testing Pool*), and any other competitor in sport who is otherwise subject to the jurisdiction of any *Signatory* or other sports organisation accepting the *Code*. All provisions of the *Code*, including, for example, *Testing* and ~~therapeutic~~Therapeutic useUse exemptionExemptions, must be applied to international- and national-level competitors. Some *National Anti-Doping Organisations* may elect to test and apply anti-doping rules to recreational-level or masters competitors who are not current or potential national-calibre competitors. *National Anti-Doping Organisations* are not required, however, to apply all aspects of the *Code* to such *Persons*. Specific national rules may be established for *Doping Control* for non-international-level or non-national-level competitors without being in conflict with the *Code*. Thus, a country could elect to test recreational-level competitors but not require ~~therapeutic~~Therapeutic useUse exemptionExemptions or whereabouts information.

In the same manner, a *Major Event Organisation* holding an *Event* only for masters-level competitors could elect to test the competitors but not require ~~therapeutic~~Therapeutic ~~use~~Use ~~exemption~~Exemptions or whereabouts information. For purposes of Article 2.8 (Administration or *Attempted Administration*) and for purposes of anti-doping information and education, any *Person* who participates in sport under the authority of any *Signatory*, government or other sports organisation accepting the *Code* is an *Athlete*.

[Comment to ~~Athletes~~athlete: This definition makes it clear that all international-and national-calibre ~~athletes~~Athletes are subject to the anti-doping rules of the *Code*, with the precise definitions of international- and national-level sport to be set forth in the anti-doping rules of the International Federations and National *Anti-Doping Organisations* respectively. At the national-~~level~~level, anti-doping rules adopted pursuant to the *Code* shall apply, at a minimum, to all persons on national teams and all persons qualified to compete in any national championship in any sport. That does not mean, however, that all such ~~athletes~~Athletes must be included in a National *Anti-Doping Organisation's Registered Testing Pool*. The definition also allows each National *Anti-Doping Organisation*, if it chooses to do so, to expand its anti-doping programme beyond national-calibre ~~athletes~~Athletes to competitors at lower levels of competition. Competitors at all levels of competition should receive the benefit of anti-doping information and education.]

**Code:** The World Anti-Doping *Code*.

**Doping Control:** All steps and processes from test distribution planning through to ultimate disposition of any appeal, including all steps and processes in between such as provision of whereabouts information, *Sample* collection and handling, laboratory analysis, ~~therapeutic~~Therapeutic ~~use~~Use ~~exemption~~Exemptions, results management and hearings.

**Event:** A series of individual *Competitions* conducted together under one ruling body (e.g. the Olympic Games, FINA World Championships, or Pan American Games).

**International Event:** An *Event* where the International Olympic Committee, the International Paralympic Committee, an International Federation, a *Major Event Organisation*, or another international sport organisation is the ruling body for the *Event* or appoints the technical officials for the *Event*.

**International-Level Athlete:** *Athletes* designated by one or more International Federations as being within the *Registered Testing Pool* for an International Federation.

**International Standard:** A standard adopted by WADA in support of the *Code*. Compliance with an *International Standard* (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the *International Standard* were performed properly. *International Standards* shall include any Technical documents issued pursuant to the *International Standard*.

**Major Event Organisations:** The continental associations of *National Olympic Committees* and other international multi-sport organisations that function as the ruling body for any continental, regional or other *International Event*.

**National Anti-Doping Organisation (NADO):** The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of *Samples*, the management of test results, and the conduct of hearings, all at the national-level. This includes an entity which may be designated by multiple countries to serve as regional *Anti-Doping Organisation* for such countries. If this designation has not been made by the competent public authority(ies), the entity shall be the country's *National Olympic Committee* or its designee.

**National Event:** A sport *Event* involving international- or national-level *Athletes* that is not an *International Event*.

**National Olympic Committee:** The organisation recognised by the International Olympic Committee. The term *National Olympic Committee* shall also include the National Sport Confederation in those countries where the National Sport Confederation assumes typical *National Olympic Committee* responsibilities in the anti-doping area.

**Person:** A natural *Person* or an organisation or other entity.

**Prohibited List:** The list identifying the *Prohibited Substances* and *Prohibited Methods*.

**Prohibited Method:** Any ~~method~~Method so described on the *Prohibited List*.

**Prohibited Substance:** Any ~~substance~~Substance so described on the *Prohibited List*.

**Registered Testing Pool:** The pool of top-level *Athletes* established separately by each International Federation and *National Anti-Doping Organisation* who are subject to both *In-Competition* and *Out-of-Competition Testing* as part of that International Federation's or *National Anti-Doping Organisation's* test distribution plan. Each International Federation shall publish a list which identifies those *Athletes* included in its *Registered Testing Pool* either by name or by clearly defined, specific criteria.

**Signatories:** Those entities signing the *Code* and agreeing to comply with the *Code*, including the International Olympic Committee, International Federations, International Paralympic Committee, *National Olympic Committees*, National Paralympic Committees, *Major Event Organisations*, *National Anti-Doping Organisations*, and WADA.

**Team sport:** A sport in which the substitution of players is permitted during a *Competition*.

**Testing:** The parts of the *Doping Control* process involving test distribution planning, *Sample* collection, *Sample* handling and *Sample* transport to the laboratory.

**Use:** The utilisation, application, ingestion, injection or consumption by any means whatsoever of any *Prohibited Substance* or *Prohibited Method*.

**WADA:** The World Anti-Doping Agency.

## **2.2 Terms defined in the International Standard for TUEs**

**Therapeutic:** Of or relating to the treatment of a medical condition by remedial agents or ~~method~~*Methods*; or providing or assisting in a cure.

**TUE:** Therapeutic Use ~~Exemption~~*Exemption* approved by a Therapeutic Use Exemption Committee based on a documented medical file before the Use of the ~~substance~~*Substance* in sports.

**TUEC:** Therapeutic Use Exemption Committee is the panel established by the relevant *Anti-Doping Organisation*.

**WADA TUEC:** The WADA Therapeutic Use Exemption Committee is the panel established by *WADA*.

3  
4

## 5 1. TUE procedure

*Athletes*, like all people, may be taken ill or find themselves in a situation that requires the ~~use~~Use of particular medications or treatments. However, the ~~substance~~Substances or ~~method~~Methods that ~~athletes~~Athletes could be required to ~~use~~Use for treatment may feature on the *Prohibited List*. In this case, a Therapeutic Use Exemption (TUE) may, under certain well-defined and restricted conditions, enable ~~athletes~~Athletes to take the necessary medication whilst competing in sporting events without resulting in a doping offence. A TUE application must be made by an ~~athlete~~Athlete to the relevant *ADO* in accordance with the International Standard for TUEs. Depending on the ~~substance~~Substance itself and the route of administration (see ~~section~~Sections 1.1.1 and 1.1.2), a TUE may be granted. In order to obtain a TUE, ~~athletes~~Athletes must have a well-documented medical condition backed up by reliable, relevant and sufficient medical data.

### ~~5.11.1.~~ ~~1.1.~~ TUE procedure

#### ~~1.1.1. 1.1.1.~~ General procedure for ~~prohibited~~Prohibited ~~substance~~Substances and ~~method~~Methods

##### ~~5.1.1~~

#### ~~5.1.1.1~~ Substances and routes of administration concerned

A TUE is required for all treatments involving the ~~use~~Use of a ~~prohibited~~Prohibited ~~substance~~Substance or ~~method~~Method ~~detailed~~Detailed as such on the *Prohibited List*.

#### ~~5.1.1.2~~ Forms

TUE applications must be submitted to the *ADO* via *ADAMS* or in paper format using the appropriate TUE form. The paper form can be obtained from the *ADO*.

#### ~~5.1.1.3~~ Submission deadline

In order to ensure that the TUE is granted to the ~~athlete~~Athlete prior to participation in a competition, all ~~athletes~~Athletes are strongly advised to submit their applications at least 30 days prior to participating in an event. For ~~substance~~Substances ~~prohibited~~Prohibited in and out of competition, the TUE application must be submitted as soon as the



medical condition requiring the ~~use~~Use of ~~prohibited~~Prohibited substanceSubstances or ~~method~~Methods is diagnosed.

#### **5.1.1.4 Approval procedure**

TUE applications will be examined by the TUEC of the relevant ADO. The ~~athlete~~Athlete will be notified of the decision taken by the TUEC. TUEC decisions will be taken during the 30 days following receipt of all of the necessary documentation and will be communicated in writing to the ~~athlete~~Athlete by the relevant ADO (see ~~section~~Section 2.2). Checks may be carried out at any time during the period of validity of the TUE by the relevant ADO or the WADA TUE Committee (see ~~section~~Section 3.2).

#### **5.1.1.5 Commencement of medical treatment**

If the TUE is approved, the ~~athlete~~Athlete may commence treatment and/or sporting practice only after receipt of notification of authorisation from the relevant organisation. (A retroactive TUE may be envisaged in the uncommon *event* of an exceptional case or emergency; see ~~section~~Section 1.1.4.)

In relation to sporting practice, ~~athletes~~Athletes should consider not using the ~~substance~~Substance prior to receiving notification of authorisation, otherwise they would be using a ~~prohibited~~Prohibited substanceSubstance or ~~method~~Method without authorisation. This would constitute an anti-doping rule violation **in the event of denial of the TUE by the TUEC.**

#### **~~5.1.2-1.1.2. Specific procedure for asthma treated with inhaled beta-2 agonists~~**

~~Since January 01, 2010, salbutamol and salmeterol when taken by inhalation at therapeutic doses are no longer on the prohibited list.~~

~~It should be noted that suprathreshold dosages may result in urinary levels of >1000 ng/ml which would be considered an AAF. In such cases, the athlete will have the burden to demonstrate, through a controlled pharmacokinetic study, that the high levels in the urine were a result of therapeutic inhaled use.~~

~~Starting on January 1<sup>st</sup>, 2011, there is no Declaration of Use required by the Prohibited List. However, note that as per the International Standard on Testing, athletes are still requested to write down all medications or substances taken in the last 7 days on the Doping Control Form, at the time of testing.~~

~~Alternate beta 2 agonists such as terbutaline and formeterol are prohibited and need a TUE from the relevant ADO. The request for a TUE should include a complete medical file with a clear explanation of why an alternate medication is being prescribed. It should be noted that the intent is not to deny the use of alternate beta 2 agonists because there is now a permitted substitute salbutamol/salmeterol particularly where a treatment regimen has already been established. However, for athletes newly diagnosed with asthma, permitted beta 2 agonists, shall be considered as the B2A of choice unless otherwise justified.~~

### ~~5.1.31.1.2. 1.1.3.~~ **Criteria for granting a TUE**

The four criteria that must be fulfilled before a TUE is granted are set forth in the International Standard for TUEs:

1. "The *Athlete* would experience a significant impairment to health if the ~~Prohibited~~*Prohibited* Substance or *Prohibited Method* were to be withheld in the course of treating an acute or chronic medical condition." (Article 4.1 a. of the International Standard for TUEs.)
2. "The ~~therapeutic~~*Therapeutic* Use of the *Prohibited Substance* or *Prohibited Method* would produce no additional enhancement of performance other than that which might be anticipated by a return to a state of normal health following the treatment of a legitimate medical condition.

The Use of any *Prohibited Substance* or *Prohibited Method* to increase "low-normal" levels of any endogenous hormone is not considered an acceptable ~~therapeutic~~*Therapeutic* intervention." (Article 4.1b of the International Standard for TUEs.)

Enhancement of performance should be taken to mean the return by the ~~athlete~~Athlete to his/her level of performance prior to the onset of the medical condition requiring treatment. This means that there may be some enhancement of individual performance as a result of the efficacy of the treatment. Nevertheless, such enhancement must not exceed the level of performance of the ~~athlete~~Athlete prior to the onset of his/her medical condition.

3. "There is no reasonable ~~therapeutic~~Therapeutic alternative to the Use of the otherwise *Prohibited Substance or Prohibited Method*." (Article 4.1 c of the International Standard for TUEs.)

Two points should be noted in relation to reasonable ~~therapeutic~~Therapeutic alternatives:

- Only valid and referenced medications are considered as alternatives.
  - The definition of what is valid and referenced may vary from one country to another. These differences should be taken into account. For example, a medication may be registered in one country and not in another, or approval may be pending, etc.
4. "The necessity for the Use of the otherwise *Prohibited Substance or Prohibited Method* cannot be a consequence, wholly or in part, of prior non-~~therapeutic~~Therapeutic Use of any ~~substance~~Substance from the *Prohibited List*." (Article 4.1 d. of the International Standard for TUEs.)

A TUE may be granted only if these four criteria are fulfilled.

#### ~~5.1.41.1.3. 1.1.4.~~ **Retroactive TUEs**

There are situations for which TUEs may be granted retroactively. Nevertheless, even if a potential retroactive TUE case is examined, under no circumstances does this provide any guarantee that the TUE will be granted. The evaluation procedure is the same as that for the standard TUE application. The application will be studied by the relevant TUEC, which will issue its decision.

In accordance with Article 4.3 of the International Standard for TUEs, the following two situations may result in a retroactive TUE:

1. Emergency treatment or treatment of an acute medical condition.

2. If, due to exceptional circumstances, there was insufficient time or opportunity for an applicant to submit, or a TUEC to consider, an application prior to *doping control*.

By way of explanation in relation to the aforementioned points:

- An emergency situation occurs when the life of an *athleteAthlete* could be at risk if he/she is unable to ~~use~~Use the ~~prohibitedProhibited~~ *substanceSubstance* or ~~methodMethod~~; in other words, if the medical condition justifies the treatment and warrants immediate administration.
- Circumstances are considered to be exceptional when, for example, a TUE cannot be granted in time through no fault of the *athleteAthlete*. Thus, an *athleteAthlete* with a chronic illness must request a TUE 30 days prior to an *event*. Nevertheless, the case of a normally healthy *athleteAthlete* suddenly affected by a significant medical condition some days prior to an *event*, and unable to request a TUE within the allotted time to enable the TUEC to grant the TUE, may be considered as an "exceptional circumstance".
- Medical emergencies or acute medical situations requiring administration of an otherwise ~~prohibitedProhibited~~ *substanceSubstance* before an application for a TUE can be made are uncommon. Similarly, circumstances requiring expedited consideration of an application for a TUE due to imminent competition are infrequent. *Anti-Doping Organisations* granting TUEs should have internal procedures that permit such situations to be addressed.

## ~~5.2~~ 1.2. Documentation/information

### ~~5.2.1~~ 1.2.1. ~~1.2.1.~~ What is sufficient?

A TUE application is deemed sufficient if it enables the *ADO* to issue a decision based on the fulfilment of the criteria set forth in the International Standard for TUEs.

As mentioned in the TUE application form, and in accordance with the International Standard for TUEs, the following documents must be attached to the completed application form in support of the application for a TUE:

© WADA World Anti-Doping Programme  
TUE Guidelines

Version ~~56.0~~  
January 201~~1~~2

- Evidence of the diagnosis must be attached.
- Copies of the original reports or letters.

The application must include a comprehensive medical history and the results of all examinations, laboratory investigations and imaging studies relevant to the application. The arguments related to the diagnosis and treatment, as well as duration of validity, should follow the *WADA "Medical Information to Support the Decisions of TUECs."* NB: Any additional relevant investigations, examinations or imaging studies requested by the TUEC of the *Anti-Doping Organisation* before approval will be undertaken at the expense of the applicant or his/her national sport governing body (Article 6.2 of the International Standard for TUEs).

- The application must include a statement by an appropriately qualified physician attesting to the necessity of the otherwise *Prohibited Substance* or *Prohibited Method* in the treatment of the *Athlete* and describing why an alternative, permitted medication cannot, or could not, be used in the treatment of this condition (Article 4.1 c. of the International Standard for TUEs).

NB: the evidence must be as objective as possible, given the clinical circumstances.

- For conditions that cannot be demonstrated, independent medical justification must be attached to the application.

The information provided must be up to date and exact, in terms of both content and form.

### **~~5.2.2~~ 1.2.2. Who decides what is sufficient?**

The *ADO* responsible for the decision (see ~~section~~Section 2.2) and, more specifically, its TUEC, decides what is sufficient. The TUEC has the right to request further information at any time if it deems such information necessary in order to issue its decision.

*WADA* can request further information from the body granting the TUE in the context of its review activity, if the evidence in support of the diagnosis is insufficient. The initial decision continues to apply during the examination of such cases by *WADA* (see ~~section~~Section 3.3.1).

### **~~5.2.3~~ 1.2.3. Incomplete TUE applications**

As mentioned in ~~section~~Section 2.1, TUE applications must be accompanied by all of the medical evidence justifying the diagnosis. It is the responsibility of the *ADO* to request any missing documentation to enable the TUEC to issue its decision.

#### **~~5.2.4~~ 1.2.4. TUE application forms**

In accordance with Article 8.5 of the International Standard for TUEs, application forms may be modified by *ADOs*. Additional requests for information may be added, but it is extremely important that all of the requests for information stipulated by *WADA* remain on the forms. No ~~section~~Sections or articles may be removed.

Furthermore, *ADOs* are advised not to add further requirements to the forms that may thwart efforts to harmonise, result in confusion or discredit the procedure. Consequently, any changes must be limited to the adaptation of the forms by *ADOs* through the inclusion of their logo and contact details, for example.

#### **~~5.2.5~~ 1.2.5. TUE applications received via *ADAMS***

Generally speaking, the evaluation part of the procedure commences upon receipt of the TUE application sent through *ADAMS* to the IFs or *NADO*. All accompanying documents should be sent as soon as possible, preferably by scanning and attaching documents to *ADAMS* file. However, accompanying documents will also be accepted via other means (e.g. fax).

#### **~~5.2.6~~ 1.2.6. Renewal of TUEs**

##### **~~5.2.6.1~~ Complete application or not?**

TUEs cannot be renewed without a new medical consultation and confirmation thereof. This means that the ~~athlete~~Athlete has to complete a new application signed by his/her physician when the previous TUE expires. Even for chronic ~~use~~Use of medication, a TUE can be granted only for a limited period.

The physician should attach a recommendation for the TUEC concerning the duration of validity of the TUE based on the next appointment scheduled with his/her patient in order to monitor the specific medical condition.

##### **~~5.2.6.2~~ Renewal option in *ADAMS***

ADAMS provides a renewal option (see ~~section~~Section 3.1.2). This option simplifies the procedure with a computerised form in which all of the fields are already completed. Nevertheless, the ~~athlete~~Athlete must obtain and submit the medical documentation in the usual manner, and the TUE will be renewed in accordance with the procedure. All application forms must be duly completed, signed and dated by the physician and the ~~athlete~~Athlete, whether this is the first application or an application for renewal.

### ~~5.2.6.3~~ **No Automatic extensions**

An automatic extension cannot be accepted under any circumstances. The physician must examine the ~~athlete~~Athlete again and determine whether the medical condition has changed and the treatment is still appropriate in relation to the declared or new medical condition.

### ~~5.2.7~~ **1.2.7. Duration of validity**

As mentioned previously, a TUE will always be granted for a limited period of time, even if ~~use~~Use of the ~~substance~~Substance is chronic. The ~~use~~Use of the ~~substance~~Substance will be regularly monitored by a physician, and the TUE will be renewed accordingly.

~~The—substance~~The Substance, dose, frequency, route and duration of administration of the otherwise *Prohibited Substance* or *Prohibited Method* in question must be specified. In case of change, a new application must be submitted. (Article 8.12 of the International Standard for TUEs.)

For advice concerning the duration of TUEs, please read the medical information to support the decisions of TUECs available on the WADA website.

## ~~5.3~~ **1.3. Languages used**

### ~~5.3.1~~ **1.3.1. Application forms**

English or French must feature on all of the forms personalised by ADOs, as well as their national language(s). In addition, all copies of applications sent to WADA must be written in English or French.

### ~~5.3.2~~ **1.3.2. Medical information**

All of the appropriate medical information necessary for the decision must also be submitted in English or French. If the file received by the ADO is not in English or French, it must be translated prior to being sent to WADA.

## **5.4 1.4. Data protection**

### **5.4.1 1.4.1. Athlete consent**

The ~~athlete~~*Athlete* should provide written consent for the transmission of all information pertaining to the application to members of the TUEC and, if necessary, to other independent medical or scientific experts, as well as all of the members of staff responsible for the management and review of TUEs and consequent appeals. The ~~athlete~~*Athlete* should also provide written consent for TUEC decisions to be distributed to other *ADOs* concerned, in accordance with the provisions of the *Code*, and for the storage of such data and its transfer to the *WADA* information centre (*ADAMS*).

### **5.4.2 1.4.2. Confidentiality clause for people working with data**

The *ADOs* and all TUECs will manage TUE applications in the strictest of confidence.

A confidentiality declaration drawn up by each *ADO* must be signed by those people responsible for the data (see Annex for a declaration template).

### **5.4.3 1.4.3. For how long is this information stored?**

Information will be stored for eight years by the relevant *ADO*. In accordance with Article 17 of the ~~WADC~~*Code*, no action may be commenced against an ~~athlete~~*Athlete* or other *person* for an anti-doping rule violation unless such action is commenced within eight years from the date upon which the violation is asserted to have occurred.

### **5.4.4 1.4.4. Modification of information**

As set forth above in ~~section~~Section 1.4.2, information concerning TUEs must be treated in the strictest of confidence. Information may be modified only by the body that granted the TUE. Consequently, the members of staff appointed by the *ADO* granting the TUE are the only people who are allowed to access the file.



## **6 2. Role of ADOs**

### **~~6.1~~ 2.1. ADO functions**

#### **~~6.1.1~~ 2.1.1. Setting up a TUEC**

This ~~section~~Section refers to Articles 6.1 to 6.3 of the International Standard for TUEs.

The *ADO* must set up a network of physicians responsible for evaluating TUE applications. TUE Committees (TUECs) should include at least three physicians with experience in the care and treatment of ~~athletes~~Athletes and a sound knowledge of clinical, sports and exercise medicine (see Article 6.1 of the International Standard for TUEs). The TUEC will be chaired by one of the member physicians.

*ADOs* may have a permanent TUEC or may set up TUECs for each individual case, depending on the expertise and availability of the experts in their network.

In practice, at least one expert should have in-depth knowledge of the specific medical sector pertaining to the application. In applications involving ~~athletes~~Athletes with disabilities, at least one TUEC member must possess specific experience with the care and treatment of ~~athletes~~Athletes with disabilities (see Article 6.1 of the International Standard for TUEs).

Thus established, the TUEC will evaluate TUE applications without delay in accordance with the International Standard for TUEs and will issue a decision on these applications. Such decision will constitute the final decision of the *ADO*. The TUEC may seek whatever medical or scientific expertise it deems appropriate in reviewing the circumstances of any application for a TUE.

#### **~~6.1.1.1~~ Conflict of interest and confidentiality**

In order to ensure a level of independence of decisions, the majority of the members of any TUEC should be free of conflicts of interest or political responsibility in the *Anti-Doping Organisation* (see Article 6.1 of the International Standard for TUEs).

Ideally, in order to avoid possible conflicts of interest, all members of TUECs should be independent of the *ADO*.

Should members of a TUEC find themselves caught in a conflict of interest in relation to their *NADO*, IF, or NF, they must be excluded from the examination of TUE applications made by ~~athletes~~*Athletes* who are members of their *NADO*, IF or NF.

Members of the TUEC must sign a conflict of interest and confidentiality declaration drawn up by the *ADO* (please see Annex 1 for a conflict of interest and confidentiality declaration template).

#### **6.1.2 2.1.2. 30-day deadline**

In accordance with the provisions of the International Standard for TUEs, which entered into force on 1 January 2010, decisions of the TUEC should be completed within thirty (30) days of receipt of all relevant documentation and will be conveyed in writing to the ~~athlete~~*Athlete* by the relevant *Anti-Doping Organisation* (see Article 8.13 of the International Standard for TUEs). In the case of a TUE application made in a reasonable time limit prior to an *event*, the TUEC of the appropriate *ADO* should ~~use~~*Use* its best endeavours to complete the TUE process before the start of the *event*.

#### **6.1.3 2.1.3. Failure to comply with the International Standard for TUEs**

An ~~athlete~~*Athlete* who has received no response to his/her TUE application after the 30-day period or before the *event* should contact the *ADO* in order to find out the status of his/her TUE application.

When an *Anti-Doping Organisation* does not respond within a reasonable period of time to a TUE application submitted in due form, such absence of a decision may be considered a denial for the purposes of rights of appeal provided for in Article 13.4 of the ~~WADC~~*Code*.

#### **6.1.4 2.1.4. Registered ~~testing~~*Testing pool***

##### **6.1.4.1 ~~Communication of registered~~*Registered testing Testing pools***

The list of ~~athletes~~*Athletes* included in *registered testing pools* will be shared among the various *ADOs* and regularly updated.

Also, IFs will communicate their *registered testing pools* to *NADOs* and NFs by posting them on their websites and clearly indicating the names of all the international-level ~~athletes~~*Athletes* included on the list at that time.

Furthermore, each IF shall publish the list of international *events* for which a TUE is required by the International Federation.

Such cooperation among ADOs will avoid duplication of tasks and will also specify the respective responsibilities of ADOs and ~~athletes~~Athletes.

#### ~~6.1.4.2~~ **Team sports**

The name of each member of a team will be communicated to the IFs by the NADOs or NFs insofar as only the NADOs and NFs know which ~~athletes~~Athletes form part of these teams. IFs may determine only which teams will be included in their ~~registered~~Registered testing~~Testing~~pool~~Pools~~.

## ~~6.2~~ **2.2. ADO jurisdiction: who grants TUEs?**

In accordance with the World Anti-Doping Code, WADA has published an International Standard for TUEs. This standard stipulates that all IFs and NADOs shall have a procedure according to which ~~athletes~~Athletes with documented medical conditions may make an application for a TUE which will be appropriately evaluated by a group of independent physicians (TUEC). The IFs and NADOs, through their respective TUECs, are therefore responsible for approving or rejecting these applications.

Depending on the level of the ~~athlete~~Athlete, IFs or NADOs grant TUEs. A TUE application may be submitted only to one body at a time. Please see ~~section~~Section 2.2.3 for the procedure to be followed by an ~~athlete~~Athlete whose competition level changes. Under certain circumstances, National Federations may also grant TUEs to national-level ~~athletes~~Athletes.

#### ~~6.2.1.1~~ **Major events**

Special protocols for TUE applications may be established on the occasion of major sporting events. ~~Major events~~Events are those organised by international multisport organisations operating as the managing body for any continental, regional or international ~~event~~Event (for example, the IOC, IPC, FISU, etc.). Thus, for Olympic Games, the IOC is considered to be an ADO with the capacity to grant TUEs to ~~athletes~~Athletes who submit an application during the Games period.

#### ~~6.2.2~~ **2.2.1. International Federations (IF) for international-level ~~athletes~~Athletes**

~~Athletes~~Athletes included in a ~~registered~~Registered testing~~Testing~~pool~~Pool~~ of an IF must obtain a TUE from the IF to which they belong. An IF may recognise, on its own authority, a TUE issued by a NADO (see ~~section~~Section 5).

Those Athletes not included in an IF Registered Testing Pool, but who participate in an International Event for which the IF requests a TUE, must apply to this same IF.

~~Those athletes not included in a registered testing pool of an IF but who participate in an international event for which the IF requests a TUE from the IF must apply to the IF in question.~~

### **6.2.3 2.2.2. National Anti-Doping Organisations (NADOs) and National Federations (NFs) for national-level athletes**

National-level ~~athletes~~Athletes and ~~athletes~~Athletes participating in national ~~events~~Events will obtain TUEs from their *NADOs*, with the exception of ~~athletes~~Athletes who have already received TUEs from an IF that are still valid, the granting of which the *NADO* has been informed (see Article 15.4 of the WADCCODE on mutual recognition).

#### **6.2.3.1 National Federations (NFs)**

When the TUEC of an NF has been set up for a given sport in accordance with the International Standard for TUEs, this body is also competent to grant TUEs.

#### **6.2.3.2 Status of continental federations**

WADA does not recognise TUEs granted by continental federations that are not currently *signatories* of the WADCCODE (unlike IFs).

#### **6.2.4 2.2.3. What must a national-level athlete do upon becoming an international-level athlete?**

A TUE application may be submitted only to one body at a time. If the level of the ~~athlete~~Athlete changes, the ~~athlete~~Athlete must submit an application to the relevant body. Thus, when a national-level ~~athlete~~Athlete with a TUE registered by his/her *NADO* becomes an international-level ~~athlete~~Athlete, he/she must submit a TUE application to his/her IF within 30 days of requiring such TUE (for example, for an ~~event~~Event).

### **6.3 2.3. Mutual recognition: ~~validity~~Validity of TUEs among *ADOs***

#### **6.3.1 2.3.1. Mutual recognition and the WADCCODE**

"Subject to the right to appeal provided in Article 13, *Testing*, ~~therapeutic~~Therapeutic use ~~exemption~~Exemptions and hearing results

or other final adjudications of any *Signatory* which are consistent with the *Code* and are within that *Signatory's* authority, shall be recognised and respected by all other *Signatories*.” (Article 15.4.1 of the [WADCCODEode](#).)

It is important to highlight the notion of “~~signatory~~Signatory’s authority” in this provision.

As explained above, IFs have international competence and international-level ~~athletes~~Athletes are under their authority, whilst NADOs have national competence and national-level ~~athletes~~Athletes are under their authority. Unless the rules of an International Federation or an agreement with an International Federation provide otherwise, *National Anti-Doping Organisations* do not have the power to grant ~~Therapeutic~~Therapeutic Use Exemptions to international-level ~~athletes~~Athletes.

“*Signatories* shall recognise the same actions of other bodies which have not accepted the *Code* if the rules of those bodies are otherwise consistent with the *Code*.” (Article 15.4.2 of the [WADCCODEode](#).)

*[Comment to Article 15.4.2: Where the decision of a body that has not accepted the Code is in some respects Code-compliant and in other respects not Code-compliant, Signatories should attempt to apply the decision in harmony with the principles of the Code. For example, if in a process consistent with the Code a non-Signatory has found an Athlete to have committed an anti-doping rule violation on account of the presence of a Prohibited Substance in his body but the period of ineligibility applied is shorter than the period provided for in the Code, then all Signatories should recognise the finding of an anti-doping rule violation and the Athlete’s National Anti-Doping Organisation should conduct a hearing consistent with Article 8 to determine whether the longer period of ineligibility provided in the Code should be imposed.]*

### **~~6-3-2~~ 2.3.2. ~~TUEs~~. TUEs granted by IFs compared to TUEs granted by NADOs and NFs**

TUEs granted by a NADO or an NF are not necessarily recognised on an ~~international~~international-level, whereas TUEs granted by an IF are valid on a national-~~level~~level.

TUEs granted by an IF are valid on a national-~~level~~level. —An ~~athlete~~Athlete participating in national events who has already received a

TUE from an IF which is still valid and the granting of which has been declared to the *NADO* is therefore not required to obtain a TUE from the *NADO* (see Article 15.4 of the [WADCCODEode](#)).

However, in order to ensure that *athletesAthletes* participating in the same international ~~event~~Event are treated fairly, IFs will not automatically recognise TUEs granted on a national ~~level~~level, given that international competitions do not fall under the authority of *NADOs*.

IFs may decide to recognise TUEs granted by certain *NADOs* (or *NFs*), in which case the IF recognises the TUE decision. Such recognition occurs provided that the procedure and the decision of the national TUEC are strictly in accordance with the IF procedure. In all other cases, a national-level *athleteAthlete* who becomes an international-level *athleteAthlete* must submit a new TUE application to the IF (see [sectionSection](#) 2.2.3).

### ~~6-3-3~~ 2.3.3. IF recognition of TUEs granted by *NADOs*

As stated above, the mutual recognition of national-level TUEs by an IF is not automatic.

In some circumstances, a mutual recognition procedure exists between *NADOs* and IFs. In such cases, the *NADO* will inform the *athleteAthlete* as to the existence of such procedure.

Should an IF decide to recognise a TUE granted by a *NADO*, it must issue a new approval notification/recognition. It therefore becomes the TUE body and will be registered as such by *WADA*.

The IF must notify the *athleteAthlete* that it has recognised the *NADO* TUE by sending the *athleteAthlete* official confirmation of such newly recognised and registered TUE.

Note that *ADAMS* has a new functionality that allows IF to recognize TUEs granted by *NADOs* without having to re-enter data.

## **6.4 2.4. Forwarding information**

The aim of this ~~section~~Section is to specify the information that must be provided and to which body.

### **6.4.1 2.4.1. NADO responsibilities**

The *NADO* will immediately send notification of all TUEs granted to ~~athletes~~Athletes in its ~~registered~~Registered testing~~Testing pool~~Pool to the relevant IF and NF.

In accordance with the International Standard for TUEs granted to ~~athletes~~Athletes included in the national or international ~~registered~~Registered testing~~Testing pool~~Pool or to international-level ~~athletes~~Athletes where the rules of the International Federation authorize *NADO* to grant TUEs to International-Level *Athletes* **must be reported to WADA through ADAMS.**

In practice, this means that, unless mutual recognition agreements exist, *NADOs* or *NFs* must send information on TUEs for their ~~athletes~~Athletes included in national ~~registered~~Registered testing~~Testing pools~~Pools to *WADA* through *ADAMS*.

### **6.4.2 2.4.2. IF responsibilities**

*IFs* must send information on all of the TUEs that they have granted to the respective *NADOs* and *NFs* of the ~~athletes~~Athletes. This will avoid duplication of work, since TUEs granted by *IFs* must be recognised and respected by *NADOs*.

*IFs* **must report** the granting of TUEs – including complete medical file - **to WADA through ADAMS.**

## **2.5. Results management**

### **6.5**

In the event of an *AAF*, the following procedure applies:

### **6.5.1 2.5.1. Results management for controls organised by an ADO**

“Upon receipt of an *A Sample Adverse Analytical Finding*, the *Anti-Doping Organisation* responsible for results management shall conduct a review to determine whether: (a) an applicable ~~therapeutic~~Therapeutic use~~Use exemption~~Exemption has been granted or will be granted as provided in the *International Standard for Therapeutic Use Exemptions*, or (b) there is any apparent departure from the *International Standard for Testing* or *International Standard for Laboratories* that caused the *Adverse Analytical Finding*.” (Article 7.1 of the ~~WADCCODE~~Code.)

#### **6.5.2 2.5.2. Consultation among ADOs**

In the *event* of an *AAF*, *ADOs* must consult to determine whether a TUE was granted. If it was correctly reported (see ~~section~~Section 2.4), the *ADOs* should already be in possession of the appropriate information.

The consultation procedure is facilitated by *ADAMS*, which enables online results management and consultation.

#### **6.5.3 2.5.3. Existing TUEs and corresponding level of ~~prohibited~~Prohibited substance~~Substance~~**

When the laboratory report reveals the presence of a ~~prohibited~~Prohibited substance~~Substance~~ or ~~method~~Method for which a TUE has been granted in accordance with the *International Standard for TUEs*, no action is required as long as the reported level corresponds to the prescribed treatment plan and authorised dose.

#### **6.5.4 2.5.4. Existing TUEs whereby the level of the ~~prohibited~~Prohibited substance~~Substance~~ does not correspond to the TUE**

If a TUE has been granted to an ~~athlete~~Athlete in accordance with the *International Standard for TUEs* but the level of the ~~prohibited~~Prohibited substance~~Substance~~ in the sample does not correspond to the authorised dose, the *ADO* must continue to follow the results management procedure applicable to ~~adverse~~Adverse analytical~~Analytical findings~~Findings.

#### **6.5.5 2.5.5. Absence of a TUE**

If the ~~athlete~~Athlete has not received a TUE in accordance with the *International Standard for TUEs*, the *ADO* must follow its rules regarding results management applicable to ~~adverse~~Adverse analytical~~Analytical findings~~Findings.

If the ~~athlete~~Athlete does not have a TUE or if the TUE is not valid, the following procedure applies:



"If the initial review of an *Adverse Analytical Finding* under Article 7.1 does not reveal an applicable ~~therapeutic~~Therapeutic use~~Use exemption~~Exemption or entitlement to a ~~therapeutic~~Therapeutic use~~Use exemption~~Exemption as provided in the *International Standard for Therapeutic Use Exemptions*, or departure that caused the *Adverse Analytical Finding*, the *Anti-Doping Organisation* shall promptly notify the *Athlete*, in the manner set out in its rules, of: (a) the *Adverse Analytical Finding*; (b) the anti-doping rule violated; (c) the *Athlete's* right to promptly request the analysis of the *B Sample* or, failing such request, that the *B Sample* analysis may be deemed waived; (d) the scheduled date, time and place for the *B Sample* analysis if the *Athlete* or *Anti-Doping Organisation* chooses to request an analysis of the *B Sample*; (e) the opportunity for the *Athlete* and/or the *Athlete's* representative to attend the *B Sample* opening and analysis within the time period specified in the *International Standard for Laboratories* if such analysis is requested; and (f) the *Athlete's* right to request copies of the A and B *Sample* laboratory documentation package which includes information as required by the *International Standard for Laboratories*. The *Anti-Doping Organisation* shall also notify the other *Anti-Doping Organisations* described in Article 14.1.2. If the *Anti-Doping Organisation* decides not to bring forward the *Adverse Analytical Finding* as an anti-doping rule violation, it shall so notify the *Athlete* and the *Anti-Doping Organisations* as described in Article 14.1.2." (Article 7.2 of the ~~WAD~~CODE~~E~~Code.)

## **7 3. Role of WADA**

WADA has the following three main roles in the TUE procedure: a role of monitoring and review on its own initiative, a role of review at the request of an ~~athlete~~Athlete, and a role of data management through ADAMS.

### **~~7.1~~ 3.1. Data management role: ADAMS**

#### **~~7.1.1~~ 3.1.1. What is ADAMS?**

The *Anti-Doping Administration and Management System (ADAMS)* is a Web-based database management tool. It is a centralised system that allows for the entry and storage of data, as well as the sharing and reporting of such data in a highly secure environment, which restricts access only to relevant authorised parties. It was designed exclusively to assist ~~stakeholders~~Stakeholders and WADA in their anti-doping operations, in strict compliance with the ~~WADCCODE~~Code.

#### **~~7.1.2~~ 3.1.2. ADAMS and TUEs**

The TUE management module in ADAMS allows for the following operations to be carried out:

- Online submission of TUE applications by ~~athletes~~Athletes;
- Online submission of TUE applications by ~~athlete~~Athlete physicians;
- Online submission of TUE applications by ADOs to TUEC physicians;
- Online management of TUE applications;
- Notification of receipt to ~~athletes~~Athletes;
- Notification of refusal to grant a TUE to ~~athletes~~Athletes;
- Sending of TUE certificates to ~~athletes~~Athletes;
- Online notification of the expiry/change in status of a TUE to relevant parties;
- Sharing of information relating to the TUE with all relevant parties;
- Recognition by IF of TUE granted by NADOs;
- Link between TUEs and AAFs;
- Search function and printing of reports.

#### **~~7.1.3~~ 3.1.3. ADAMS and ~~athletes~~Athletes**

ADAMS will enable ~~athletes~~Athletes to complete forms and submit their TUE applications online, receive online notification from ADOs and consult changes in the approval status of their applications.

#### ~~7.1.4~~ **3.1.4. ADAMS and physicians**

*Athletes'* physicians may complete TUE application forms for their patients online after identifying themselves to their patients' ADO.

#### ~~7.1.5~~ **3.1.5. ADAMS and ADOs**

ADAMS enables ADOs to manage TUE applications online. ADOs may grant or deny TUEs online and send notification to ~~athletes~~Athletes. ADOs may confirm whether a TUE is being reviewed by WADA.

### ~~7.2~~ **3.2. Role of monitoring and reviewing TUEs on its own initiative**

In accordance with Article 4.4 of the ~~WADCCODE~~Code, the WADA TUEC may review, on its own initiative, the granting of a TUE to an international-level ~~athlete~~Athlete or a national-level ~~athlete~~Athlete in a ~~NADO registered~~Registered testing~~Testing pool~~Pool.

If WADA determines that the granting or denial of a TUE does not comply with the International Standard for TUEs in force at the time, it may overturn the decision and the TUE will be invalidated. Should a decision be overturned, WADA will advise all of the relevant parties (the ~~athlete~~Athlete, the IF, the NADO and the NF).

### ~~7.3~~ **3.3. Role of reviewing TUEs at the request of an ~~athlete~~Athlete**

In accordance with Article 4.4 of the ~~WADCCODE~~Code, an ~~international~~International-level~~Level~~ ~~athlete~~Athlete or a national-level ~~athlete~~Athlete who has been denied a TUE may request that this decision be reviewed by the WADA TUEC.

#### ~~7.3.1~~ **3.3.1. TUE review procedure**

##### ~~7.3.1.1~~

##### **WADA review request procedure**

The request to WADA to review the decision is the first possible phase in the review of a TUE.

As set forth in Article 4.4 of the ~~WADCCODE~~Code, WADA may review a TUE denial at the request of an international-level ~~athlete~~Athlete or a national-level ~~athlete~~Athlete in a ~~registered~~Registered testing~~Testing pool~~Pool.

The ~~athlete~~Athlete must send the request for a review of his/her case by registered letter to WADA. The ~~athlete~~Athlete must provide all of the information sent during the initial submission (complete file), along with the initial decision issued and the explanation provided by the ADO as to why the TUE was not granted.

The certificate of payment of the required application fee (USD 500) must be included in the request. Such fee is non-refundable, regardless of the result of the review procedure. WADA will provide all of the bank information concerning the payment of such fee upon request.

The review procedure will commence upon receipt of payment and all of the necessary documentation by WADA.

Upon receipt of the complete request for review, WADA will set up and coordinate the WADA TUEC, which will review the case and issue its decision within a maximum of thirty (30) days. WADA will inform all of the relevant parties as to the decision issued.

WADA will review the decision taken by the IF or the NADO on the basis of a file identical to that which was submitted to the same IF or NADO. No additional medical information/data will be taken into account.

The International Standard for TUEs currently makes no mention of the period during which an ~~athlete~~Athlete may request a review of the TUE. If necessary, the time set forth in the rules of the IF or NADO will apply.

### **~~7.3.1.2~~ Status of a TUE during the WADA review procedure**

The review procedure does not suspend the initial decision. As such, the initial decision remains in effect throughout the duration of the procedure until the decision is issued. Consequently, **the ~~athlete~~Athlete is not allowed to ~~use~~Use the ~~substance~~Substance or ~~method~~Method whilst awaiting the decision from WADA if he was initially denied the TUE.**

If WADA overturns the initial decision and grants the TUE, the ~~athlete~~Athlete may then start to ~~use~~Use the ~~substance~~Substance or ~~method~~Method in accordance with the TUE granted. Nevertheless, the ADO that issued the first decision has a right to appeal the decision handed down by WADA before the CAS, which will make a final ruling (see ~~section~~Section 3.3.2 below). The WADA decision will remain in effect until the CAS hands down the final decision.

---

---

---

---

### **7.3.2 3.3.2. Appeal of decisions handed down by WADA**

#### **7.3.2.1**

##### **Appeal procedure**

The decision handed down by WADA may be appealed in the following manner (see Article 13.3 of the [WADCCODE](#)):

If the initial decision is **overturned** by WADA, only the *athlete* or the ADO whose decision was invalidated may appeal this decision before the CAS.

If the initial decision denying a TUE **is not invalidated** by WADA, the WADA decision may be appealed:

- Before the CAS by international-level *athletes*, or
- Before the national-level review body by other *athletes*. In this case, if the national-level review body invalidates the decision to deny the TUE, WADA may appeal such decision before the CAS.

CAS decisions on TUEs are final.

#### **7.3.2.2 The role and scope of review of the CAS**

The CAS has a limited role, as it does not act as a substitute for TUE Committees.

Unlike TUE Committees (TUECs), CAS panels are not made up of physicians. As such, they do not have the medical expertise of TUECs. The CAS may consider that a TUE Committee has unduly rejected a TUE application only on the basis of particularly convincing elements contained in the TUE application file (CAS 2004/A/769).

Furthermore, the CAS cannot hand down a decision based on facts and other evidence that were not submitted to the relevant TUE Committee with the TUE application. Indeed, “In principle, an *athlete* ~~is~~ is not allowed to ask the CAS to hand down a decision based on facts and other evidence that have not been submitted to the relevant TUE committee Committee with the TUE application” (CAS 2004/A/769).~~—~~.

**No additional medical information/data may be submitted.**—The review or appeal must be considered based on documents identical to those resulting in the initial decision.

### **7.3.2.3**

#### **Time limit**

The time limit depends on the rules of each organisation. Particular attention will be paid to the following article in the CAS rules, which deals with the arbitration procedure for appeals:

“In the absence of a time limit set in the statutes or regulations of the federation, association or sports-related body concerned, or of a previous agreement, the time limit for appeal shall be twenty-one days from the receipt of the decision appealed against. After having consulted the parties, the Division President may refuse to entertain an appeal if it is manifestly late.” (Section C, Article R49, CAS, Statutes of the Bodies Working for the Settlement of Sports-related Disputes.)

## References

*WADA, World Anti-Doping Code, 2009.*

*WADA, International Standard for Therapeutic Use Exemptions, which entered into force on 1 January 2010.*

*WADA, Model Rules for International Federations.*

*WADA, Model Rules for National Anti-Doping Organisations.*

*WADA, Q&A: International Standard for Therapeutic Use Exemptions, 2009.*

*CAS, Statutes of the Bodies Working for the Settlement of Sports-related Disputes.*

## Annex

### CONFLICT OF INTEREST AND CONFIDENTIALITY DECLARATION

As a member of the TUE *Committee* of [name of the organisation], I, the undersigned, \_\_\_\_\_, ~~— affirm —~~ and acknowledge that, by signing this declaration, I am bound by the terms of such declaration.

I understand that the nature of my participation as a member of the aforementioned committee is such that I shall come into contact with or be made aware of sensitive and confidential information.

I swear or solemnly state that, as a member of the TUE *Committee* of [name of the organisation], I shall respect all of the requirements relating to the confidentiality of the information that I receive or that is brought to my attention in any way whatsoever during the course of my duties and functions throughout and beyond the duration of my participation.

With the exception of legal obligations, authorisation by virtue of my office, or the express authorisation of [*person* in charge of your organisation], I shall not reveal or hand over to anybody, particularly to representatives of the media, any confidential information or document that is brought to my attention or is in my possession, either directly or indirectly through my participation as a member of the TUE *Committee* of [name of the organisation], excluding information that has already been made public or is in my possession independently of [name of the organisation]. I shall not ~~use~~Use my title as member of the committee for any public declaration.

I, the undersigned, acknowledge that [name of the organisation] holds all of the property rights and titles to all of the material, copies, extracts, summaries and other confidential information drawn up during my participation as a member of the TUE *Committee* of [name of the organisation].

Furthermore, I understand that the violation of my confidentiality obligation may result in possible legal proceedings against me and the immediate termination of my participation as a member of the TUE *Committee* of [name of the organisation].

In the *event* of any conflict of interest with a party to the application for a Therapeutic Use Exemption that the TUE *Committee* of [name of the organisation] may have to handle, I shall immediately inform [*person* in charge of the organisation] and abstain from taking part in the decision procedure for the specific case in question.

DATED THE \_\_\_\_\_ DAY OF \_\_\_\_\_, 20\_\_\_\_\_



BY \_\_\_\_\_

(SIGNATURE)